Boston Scientific Acquires BTG plc

Boston Scientific To Acquire Penumbra, Inc. for About $14.5 Billion

January 16, 2026

Medical Devices

Boston Scientific signed a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock transaction valued at about $14.5 billion on an enterprise value basis. The deal is designed to broaden Boston Scientific’s vascular and neurovascular portfolio, particularly in mechanical thrombectomy and adjacent neurovascular markets, with expected closing in 2026 subject to regulatory approvals and Penumbra shareholder approval.

Pfizer Acquires Global Blood Therapeutics (GBT) for $5.4 Billion

August 8, 2022

Biotechnology

Pfizer entered into a definitive agreement to acquire Global Blood Therapeutics (GBT), paying $68.50 per share in cash for an enterprise value of about $5.4 billion. The deal adds GBT’s sickle cell disease portfolio, including Oxbryta (voxelotor), along with clinical pipeline assets such as GBT021601 (GBT601) and inclacumab.

Valtech Acquires The Berndt Group (TBG)

April 7, 2022

Healthcare Services

Valtech, a global business transformation agency, has acquired The Berndt Group (TBG), a Baltimore-based digital customer experience agency focused on digital health transformations. TBG’s team of more than 80 practitioners and health-system clients (including Johns Hopkins and Penn Medicine) will bolster Valtech’s healthcare and digital experience capabilities.

Boston Scientific Acquires Baylis Medical Company Inc.

October 6, 2021

Medical Devices

Boston Scientific Corporation entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The acquisition is expected to expand Boston Scientific’s electrophysiology and structural heart portfolios by adding the RF NRG and VersaCross transseptal platforms and related guidewires, sheaths, and dilators.

Boston Scientific Acquires Lumenis Surgical Business from Baring Private Equity Asia for $1.07B

March 3, 2021

Medical Devices

Boston Scientific has agreed to acquire the Lumenis Surgical Business from Baring Private Equity Asia/Lumenis for USD 1.07 billion, subject to closing adjustments. The deal transfers Lumenis' surgical laser portfolio and global surgical team (including its Israeli laser center of excellence) to Boston Scientific to bolster its Urology strategy, while Lumenis — still owned by BPEA — will focus on Aesthetics and Vision.

Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific

December 1, 2020

Pharmaceuticals

Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.